Linjuan Guo

Dr. Linjuan Guo

Department of Cardiology, Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2024 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
WZWengen Zhu
Wengen Zhu
YZYue Zhou
Yue Zhou
LGLinjuan Guo
Linjuan Guo
SFShenghui Feng
Shenghui Feng
Sialic acids are predominantly found at the terminal ends of glycoproteins and glycolipids and play key roles in cellular communication and function. The process of sialylation, a form of post-translational modification, involves the covalent attachment of sialic acid to the terminal residues of oligosaccharides and glycoproteins. This modification not only provides a layer of electrostatic repulsion to cells but also serves as a receptor for various biological signaling pathways. Sialylation is involved in several pathophysiological processes. Given its multifaceted involvement in cellular functions, sialylation presents a promising avenue for therapeutic intervention. Current studies are exploring agents that target sialic acid residues on sialoglycans or the sialylation process. These efforts are particularly focused on the fields of cancer therapy, stroke treatment, antiviral strategies, and therapies for central nervous system disorders. In this review, we aimed to summarize the biological functions of sialic acid and the process of sialylation, explore their roles in various pathophysiological contexts, and discuss their potential applications in the development of novel therapeutics.

5 August 2025 in Heart Rhythm
Verified
Journal Article
Open access
WKWulamiding Kaisaier
Wulamiding Kaisaier
ZXZixuan Xu
Zixuan Xu
LGLinjuan Guo
Linjuan Guo
YDYugang Dong
Yugang Dong
YCYili Chen
Yili Chen
WZWengen Zhu
Wengen Zhu
Left atrial appendage closure (LAAC) is primarily indicated for stroke prevention in patients with atrial fibrillation (AF) who have contraindications to long-term oral anticoagulants (OACs). However, the long-term comparative benefits of LAAC vs OACs in the broader AF population remain unclear. To study aimed to assess the long-term efficacy and safety of LAAC compared with OACs in patients with AF, we conducted a meta-analysis of randomized controlled trials (RCTs). We systematically searched PubMed, Embase, and Cochrane Library for eligible RCTs. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using fixed-effects models. Four RCTs involving 3116 patients with AF (1736 assigned to LAAC and 1380 to OACs) and follow-up durations ranging from 36 to 49.6 months were included. Compared with OACs, LAAC was associated with reduced risks of all-cause death (RR = 0.78; 95% CI: 0.64-0.95) and cardiovascular or unexplained death (RR = 0.69; 95% CI: 0.51-0.94). There were no significant differences between the 2 groups in stroke or systemic embolism, ischemic stroke, or systemic embolism, and non-cardiovascular death. LAAC was associated with significantly lower risk of hemorrhagic stroke (RR = 0.34; 95% CI: 0.16-0.76) and non-procedural clinically relevant bleeding (RR = 0.49; 95% CI: 0.40-0.61). Major bleeding (including procedural and non-procedural) risk did not differ significantly between groups. In this meta-analysis of RCTs, LAAC was associated with significantly lower risks of all-cause and cardiovascular death, hemorrhagic stroke, and non-procedural clinically relevant bleeding compared with OACs, without increasing the risk of thromboembolic events or major bleeding. These findings support the consideration of LAAC as an alternative to OAC in selected patients with AF.

30 April 2025 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
MHMingrui Han
Mingrui Han
WHWenfeng He
Wenfeng He
WZWengen Zhu
Wengen Zhu
LGLinjuan Guo
Linjuan Guo
Lactate, the end product of glycolysis, plays a crucial role in cellular signaling and metabolism. The discovery of lactylation, a novel post-translational modification, has uncovered the role of lactate in regulating diseases, especially in the brain. Lactylation connects genetic encoding with protein function, thereby influencing key biological processes. Increasing evidence supports lactate-mediated lactylation as a critical modulator in neurological disorders. This review offers an overview of lactate metabolism and lactylation, highlighting recent advances in understanding the regulatory enzymes of lactylation and their role in the central nervous system. We investigate the impact of lactylation on brain dysfunctions, including neurodegenerative diseases, cerebrovascular disorders, neuroinflammation, brain tumors, and psychiatric conditions. Moreover, we highlight the therapeutic potential of targeting lactylation in treating brain disorders and outline key research gaps and future directions needed to advance this promising field.

11 January 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
LGLinjuan Guo
Linjuan Guo
XLXiao Liu
Xiao Liu
PYPeng Yu
Peng Yu
WZWengen Zhu
Wengen Zhu
Background: Overweight and mildly obese individuals have a lower risk of death than their normal-weight counterparts; this phenomenon is termed “obesity paradox.” Whether this “obesity paradox” exists in patients with heart failure (HF) or can be modified by comorbidities is still controversial. Our current study aimed to determine the association of body mass index (BMI) with outcomes with patients with HF with preserved ejection fraction (HFpEF) with or without coexisting atrial fibrillation (AF).Methods: Patients with HFpEF from the Americas in the TOPCAT trial were categorized into the 3 groups: normal weight (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2), and obesity (≥30 kg/m2). The Cox proportional-hazards models were used to calculate the adjusted hazard ratios (HRs) and CIs.Results: We identified 1,749 patients with HFpEF, 42.1% of which had baseline AF. In the total population of HFpEF, both overweight (HR = 0.59, 95% CI: 0.42–0.83) and obesity (HR = 0.49, 95% CI: 0.35–0.69) were associated with a reduced risk of all-cause death. Among patients with HFpEF without AF, overweight (HR = 0.51, 95% CI: 0.27–0.95) and obesity (HR = 0.64, 95% CI: 0.43–0.98) were associated with a lower risk of all-cause death. In those with AF, obesity (HR = 0.62, 95% CI: 0.40–0.95) but not overweight (HR = 0.81, 95% CI: 0.54–1.21) was associated with a decreased risk of all-cause death.Conclusions: The “obesity paradox” assessed by BMI exists in patients with HFpEF regardless of comorbid AF.Clinical Trial Registration:https://clinicaltrials.gov, identifier: NCT00094302.

5 January 2023 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
XLXuyang Liu
Xuyang Liu
SWShengnan Wang
Shengnan Wang
WHWenfeng He
Wenfeng He
LGLinjuan Guo
Linjuan Guo
Background: The 2021 UK National Institute for Health and Care Excellence guidelines tend to recommend the ORBIT score for predicting bleeding risk in patients with atrial fibrillation (AF) with anticoagulants. Herein, we comprehensively re-assessed the predicted abilities of the HAS-BLED vs. ORBIT score since several newly published data showed different findings.Methods: We comprehensively searched the PubMed electronic database until December 2021 to identify relevant studies reporting the ORBIT vs. HAS-BLED scores in anticoagulated patients with AF. Their predicted abilities were assessed using the C-index, reclassification, and calibration analysis.Results: Finally, 17 studies were included in this review. In the pooled analysis, the ORBIT score had a C-index of 0.63 (0.60–0.66), 0.59 (0.53–0.66), and 0.57 (0.48–0.67) for major bleeding, any clinically relevant bleeding, and intracranial bleeding, respectively, while the HAS-BLED score had a C-index of 0.61 (0.59–0.63), 0.59 (0.56–0.63), and 0.57 (0.51–0.64) for major bleeding, any clinically relevant bleeding, and intracranial bleeding, respectively. There were no statistical differences in the accuracy of predicting these bleeding events between the two scoring systems. For the outcome of major bleeding, the subgroup analyses based on vitamin K antagonists vs. direct oral anticoagulants suggested no differences in the discrimination ability between the HAS-BLED and ORBIT scores. Reclassification and calibration analyses of HAS-BLED vs. ORBIT should be further assessed due to the limited and conflicting data.Conclusion: Our current findings suggested that the HAS-BLED and ORBIT scores at least had similar predictive abilities for major bleeding risk in anticoagulated (vitamin K antagonists or direct oral anticoagulants) patients with AF, supporting the use of the HAS-BLED score in clinical practice.

19 August 2025 in Pharmacological Research
Verified
Journal Article
Open access
SFShenghui Feng
Shenghui Feng
YZYue Zhou
Yue Zhou
LGLinjuan Guo
Linjuan Guo
YLYan Liang
Yan Liang
WZWengen Zhu
Wengen Zhu
Cardiometabolic diseases (CMDs), encompassing both cardiovascular diseases and metabolic syndromes, are among the leading causes of global morbidity and mortality. Protein S-palmitoylation, a reversible lipid-based post-translational modification, has emerged as a crucial regulator of cellular function and homeostasis. Palmitoylation is catalysed by palmitoyl transferases (PATs), also known as ZDHHC (zinc finger Asp-His-His-Cys) proteins, while a series of deacylases mediate the process of depalmitoylation. By modulating protein hydrophobicity, stability, subcellular localization, enzymatic activity, and membrane trafficking, palmitoylation exerts profound effects on cellular function. Physiologically, maintaining normal palmitoylation-depalmitoylation cycle are crucial in regulating the activity and membrane localization of ion channels involved in cardiomyocyte electrophysiology, modulating endothelial metabolism, cell-cell interactions, and repair following vascular injury, as well as influencing insulin signalling in cardiomyocyte metabolism. In the aspect of pathogenesis, palmitoylation influences the development of CMDs such as coronary artery disease (CAD), heart failure (HF), hypertension, type 2 diabetes (T2D), diabetic cardiomyopathy (DbCM), obesity, and non-alcoholic fatty liver disease (NAFLD). Dysregulation of the palmitoylation-depalmitoylation cycle contributes to these pathological processes, exacerbating disease progression. This review systematically explores the biological functions of palmitoylation in cardiometabolic physiology and diseases, discussing potential therapeutic targets within the palmitoylation pathway. By maintaining normal palmitoylation-depalmitoylation cycle and preventing its dysregulation, novel strategies for the prevention and treatment of CMDs may be developed.